Elzbieta Kania

Elzbieta Kania

Auto-generated profile, based on publicly available information

Elzbieta Kania

Tumour Cell Death and Autophagy Laboratory, Cancer Research UK Beatson Institute, Glasgow, G61 1BD, United Kingdom

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 July 2022 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
JLJaclyn S. Long
Jaclyn S. Long
EKElżbieta Kania
Elżbieta Kania
DMDavid G. McEwan
David G. McEwan
VBValentin Barthet
Valentin Barthet
MBMartina Brucoli
Martina Brucoli
KRKevin M. Ryan
Kevin M. Ryan
The role of autophagy in cancer is complex. Both tumor-promoting and tumor-suppressive effects are reported, with tumor type, stage and specific genetic lesions dictating the role. This calls for analysis in models that best recapitulate each tumor type, from initiation to metastatic disease, to specifically understand the contribution of autophagy in each context. Here, we report the effects of deleting the essential autophagy gene Atg7 in a model of pancreatic ductal adenocarcinoma (PDAC), in which mutant Kras G12D and mutant Trp53 172H are induced in adult tissue leading to metastatic PDAC. This revealed that Atg7 loss in the presence of Kras G12D /+ and Trp53 172H /+ was tumor promoting, similar to previous observations in tumors driven by embryonic Kras G12D /+ and deletion of Trp53 . However, Atg7 hemizygosity also enhanced tumor initiation and progression, even though this did not ablate autophagy. Moreover, despite this enhanced progression, fewer Atg7 hemizygous mice had metastases compared with animals wild type for this allele, indicating that ATG7 is a promoter of metastasis. We show, in addition, that Atg7 +/− tumors have comparatively lower levels of succinate, and that cells derived from Atg7 +/− tumors are also less invasive than those from Atg7 +/+ tumors. This effect on invasion can be rescued by ectopic expression of Atg7 in Atg7 +/− cells, without affecting the autophagic capacity of the cells, or by treatment with a cell-permeable analog of succinate. These findings therefore show that ATG7 has roles in invasion and metastasis that are not related to the role of the protein in the regulation of autophagy.

5 October 2025 in bioRxiv
Verified
Preprint
Open access
EREvie Rigby
Evie Rigby
ANAkshara Narayanan
Akshara Narayanan
EKElzbieta Kania
Elzbieta Kania
JHJohn A Harris
John A Harris
JWJamie Williams
Jamie Williams
KKKaren Keeshan
Karen Keeshan
The myeloid oncogene TRIB2 is a key driver of acute myeloid leukaemia (AML) pathogenesis, promoting chemoresistance and blocking differentiation through ubiquitin-mediated degradation of the C/EBPα transcription factor. Despite its stable and sometimes elevated expression across AML subtypes, TRIB2 remains a clinically-untargeted vulnerability. Here, we present a comprehensive investigation into TRIB2 degradation mechanisms using multimodal approaches, including CRISPR knockout, mutational protein stability, small molecule TRIB2 engagement and evaluation of a novel targeted protein degrader (TRIB2-PROTAC). We identify Afatinib, a multi-ERBB covalent inhibitor, as a rapid inducer of TRIB2 degradation, triggering AML cell death via an ERBB-independent pathway. Importantly, TRIB2 degradation synergized with cytarabine, the frontline AML chemotherapy, amplifying therapeutic efficacy. Mapping of TRIB2 ubiquitination sites revealed Lys-63 as critical for its own proteolytic turnover, and a Lys to Arg degradation-resistant mutant (K all R) conferred enhanced chemoresistance and increased leukaemic engraftment in vivo . CRISPR-mediated TRIB2 knockout validated an essential role in AML cell survival. Consistently, the novel TRIB2-PROTAC (compound 5K) achieved robust TRIB2 degradation and AML cell killing at low micromolar concentrations. These findings establish TRIB2 as a compelling therapeutic target in AML and demonstrate that leveraging the ubiquitin-proteasome system to degrade TRIB2 offers a promising strategy to overcome chemoresistance. This work provides strong preclinical rationale for the development of TRIB2-targeting therapies in AML.